Leukapheresis Devices Market

Leukaemia is a medical procedure that involves separating white blood cells from a sample of blood. The procedure is undergone to reduce the quantity of white blood cells in patients wuth hematological malignancies. Therefore, leukapheresis devices are the medical devices that are used to facilitate this procedure. The surge in demand for leukopaks in clinical research is one of the major factors fostering the growth of the market. Growth in the number of activities associated with blood donations coupled with growing innovations and advancements in technologies is another market growth determinant. Rising health awareness among individuals, growing approvals for processes of isolating white blood cells (WBC), and rising medical tourism are other important factors that will further generate lucrative market growth opportunities.

Market Dynamics

This global leukapheresis devices market report provides details of recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. For instance, In December 2021, ExThera Medical develops revolutionary medical devices that address unmet clinical needs in the treatment of bloodstream infections and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, entered into an exclusive distribution agreement in Japan for ExThera's Seraph 100 Microbind Affinity Blood Filter (Seraph 100). As per the agreement structure, ExThera Medical and Asahi Kasei Medical will collaborate to obtain regulatory approval for Seraph 100 for commercialization in Japan. The global leukapheresis devices market is expected to witness significant growth during the forecast period, owing to the increasing prevalence of leukemia. For instance, in June 2022, Terumo Blood is in blood component, therapeutic apheresis and cellular technologies and Cell Technologies, a medical technology company specializing in a portfolio of products, software, and services for blood component collection, therapeutic apheresis, and cellular technologies, announced it had signed a new collaborative agreement with GenCure, a subsidiary of BioBridge Global, to extend and unify cell and gene therapy manufacturing solutions.

Key features of the study:

• This report provides an in-depth analysis of the global leukapheresis devices market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global leukapheresis devices market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Asahi Kasei Medical Co. Ltd., Haemonetics Corporation, Terumo BCT Inc., STEMCELL Technologies Inc., Fresenius SE & Co. KGaA, BioIVT, Grifols, S.A, HemaCare, B. Braun Melsungen AG, Caltag Medsystems Limited, AllCells, StemExpress, PPA, Cellero, Precision for Medicine, Inc., The Intelligent Tissue Group Lonza, BioIVT, Lmb Technologie GmbH, Kaneka Medical Europe N.V. and Key Biologics, LLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding its future product launches, type up-gradation, market expansion, and marketing tactic
• The global leukapheresis devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global leukapheresis devices market

Detailed Segmentation:

• Global Leukapheresis Devices Market, By Device Type:
  • Apheresis Devices
  • Leukapheresis Columns & Cell Separators
  • Leukoreduction Filters
  • Leukapheresis Disposables
• Global Leukapheresis Devices Market, By Application :
  • Research Applications
  • Therapeutic Applications
• Global Leukapheresis Devices Market, By End User:
  • Hospitals
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Blood Component Providers
  • Blood Centers
• Global Leukapheresis Devices Market , By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Asahi Kasei Medical Co. Ltd.
  • Haemonetics Corporation
  • Terumo BCT Inc.
  • STEMCELL Technologies Inc.
  • Fresenius SE & Co. KGaA
  • BioIVT, Grifols, S.A
  • HemaCare
  • Braun Melsungen AG
  • Caltag Medsystems Limited
  • AllCells
  • StemExpress
  • PPA
  • Cellero
  • Precision for Medicine, Inc.
  • The Intelligent Tissue Group Lonza
  • BioIVT
  • Lmb Technologie GmbH
  • Kaneka Medical Europe N.V.
  • Key Biologics, LLC.